Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis

Trial Identifier:	D9480R00033
Sponsor:	AstraZeneca
NCTID::	NCT04799067
Start Date:	May 2021
Primary Completion Date:	July 2022
Study Completion Date:	July 2022
Condition:	Chronic Kidney Diseases; Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, Beijing	Beijing, China
China, Guangdong	Guangzhou, Guangdong, China
China, Guangdong	Shenzhen, Guangdong, China
China, Hebei	Shijiazhuang, Hebei, China
China, Hubei	Taihe, Hubei, China
China, Jiangxi	Nanchang, Jiangxi, China
China, Liaoning	Shenyang, Liaoning, China
China, Shanghai	Shanghai, China, 2000127
China, Shanxi	Taiyuan, Shanxi, China
China, Shanxi	Yangquan, Shanxi, China
China, Zhejiang	Ningbo, Zhejiang, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company